2025-12-19 - Analysis Report
Okay, let's analyze Recursion Pharmaceuticals (RXRX) based on the provided data.

**0) Overview**

Here's a breakdown of the data, followed by a more comprehensive analysis:

**1) Return Rate Comparison**

*   **RXRX:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company using machine learning to discover, develop, and commercialize novel therapeutics.
*   **RXRX Cumulative Return:** -28.11%
*   **VOO (S&P 500) Cumulative Return:** 41.08%
*   **Divergence:** -73.8 (Relative Divergence: 0.4)

**Analysis:** RXRX has significantly underperformed the S&P 500. The divergence is substantial, indicating a strong negative correlation in performance over the covered period. The relative divergence indicates that this underperformance is near its worst point in the observed range.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 22.0% | 81.0% | 26.0% | -0.2 | 5.1 |
| 2022-2024  | 11.0% | 81.0% | -10.0% | 0.1 | 3.5 |
| 2023-2025  | 14.0% | 80.0% | -49.0% | 0.1 | 2.3 |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate fluctuates, showing some growth but inconsistent performance.
*   **MDD:** The Maximum Drawdown is consistently high (around 80%), indicating significant risk and volatility.
*   **Alpha:** Alpha has decreased significantly over time. The negative Alpha in recent periods suggests underperformance relative to its risk (beta).
*   **Beta:** The Beta is low (around 0.1 or -0.2), suggesting low correlation with the market (S&P 500).
*   **Cap(B):** The market capitalization has been decreasing over the 3-year periods.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 4.44
*   **Previous Close:** 4.68
*   **Change:** -5.13%
*   **5-day SMA:** 4.37
*   **20-day SMA:** 4.4773
*   **60-day SMA:** 5.0279

**Analysis:** The stock price is currently below its 5-day and 20-day moving averages, indicating a recent downward trend. The fact that the 60-day SMA is higher suggests that the longer-term trend was previously upward, but the recent decline is pulling the price down.

**3) RSI, PPO, and Expected Return**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 45.41
*   **PPO:** 0.3474
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change:** -4.7 (Short-term decline)
*   **Expected Return:** -540.8%

**Analysis:**

*   **MRI:** The Market Risk Indicator suggests a medium investment recommendation.
*   **RSI:** The RSI is near neutral, suggesting the stock is neither overbought nor oversold.
*   **PPO:** The PPO is slightly positive.
*   **Hybrid Signal:** The "Hybrid Signal" suggests a relatively aggressive "buy" recommendation, driven by the high MRI score of 0.9.
*   **Recent Relative Divergence Change:** The decline in relative divergence confirms the recent underperformance against the S&P 500.
*   **Expected Return:** The extremely negative expected return is concerning and highlights the significant risk associated with this stock.

**4) Recent News & Significant Events**

*   **Positive News:** The stock received an upgrade from JPMorgan, citing momentum in the REC-4881 trial. Several articles highlight this upgrade and positive trial data.
*   **Mixed News:** Some articles analyze the recent price dive, suggesting caution despite the positive news.
*   **Overall:** The news is a mix of positive catalysts (JPMorgan upgrade, trial data) and cautionary analysis regarding recent performance.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.5 - around Hold)
*   **Target Price:** 7.00 (Avg), 11.00 (High), 3.00 (Low)

**Analysis:** Analysts, on average, have a cautiously optimistic view, with a consensus rating near "Hold." The average target price is significantly higher than the current price, suggesting potential upside. The range of target prices is wide, indicating uncertainty. The JPMorgan upgrade likely influenced these opinions.

**5) Recent Earnings Analysis**

| 날짜        | EPS    | 매출     |
|-------------|--------|----------|
| 2025-11-05 | -0.36  | 0.01 B$  |
| 2025-08-05 | -0.41  | 0.02 B$  |
| 2025-05-05 | -0.5   | 0.01 B$  |
| 2024-11-06 | -0.34  | 0.03 B$  |
| 2025-11-05 | -0.34 | 0.03 B$ |

**Analysis:** The company is consistently losing money, with negative EPS in all reported quarters. Revenue is low and fluctuating. This further reinforces the risk associated with the stock.  It seems there may be duplicate data.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.00B  | -194.74%      |
| 2025-06-30 | $0.02B  | -5.54%        |
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-09-30 | $1.05B  | -15.50%  |
| 2025-06-30 | $0.92B  | -18.70%  |
| 2025-03-31 | $0.93B  | -21.68%  |
| 2024-12-31 | $1.03B  | -17.29%  |
| 2024-09-30 | $0.52B  | -18.27%  |

**Analysis:**

*   **Revenue:** Revenue generation is inconsistent and generally low.
*   **Profit Margin:** Profit margins are generally negative, reflecting the company's inability to generate profit from its sales. The negative percentages often exceed 100%, indicating significant losses relative to revenue.
*   **Equity:** Equity has fluctuated and slightly increased during the period.
*   **ROE:** Return on Equity is consistently negative, indicating poor profitability from shareholder investments.

**7) Comprehensive Analysis**

*   **Negative Performance:** RXRX has significantly underperformed the S&P 500, and the recent trend is downward.
*   **High Risk:** The high maximum drawdown and negative expected return indicate substantial risk.
*   **Uncertain Profitability:** The company is currently unprofitable, with negative EPS and ROE.
*   **Mixed Signals:** While the JPMorgan upgrade and positive trial data provide a potential catalyst, recent price declines, analyst uncertainty (wide target price range), and consistent losses raise concerns.
*   **Analyst Optimism:** The buy consensus represents a potentially positive outlook for the stock.

**Conclusion:**

Investing in RXRX appears highly speculative. While positive news and analyst ratings provide some hope, the underlying financials and market performance indicate significant risk. Investors should carefully consider their risk tolerance and conduct further due diligence before investing in this stock. The company needs to demonstrate consistent revenue growth and a path to profitability to justify a more bullish outlook.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.